Current and future immunotherapy-based treatments for oesophageal cancers.
To, Natalie Evans, Richard P T Pearce, Hayden Kamarajah, Sivesh K Moss, Paul Griffiths, Ewen A
To, Natalie
Evans, Richard P T
Pearce, Hayden
Kamarajah, Sivesh K
Moss, Paul
Griffiths, Ewen A
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-06-24
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Oesophageal cancer is a disease that causes significant morbidity and mortality worldwide, and the prognosis of this condition has hardly improved in the past few years. Standard treatment includes a combination of chemotherapy, radiotherapy and surgery; however, only a proportion of patients go on to treatment intended to cure the disease due to the late presentation of this disease. New treatment options are of utmost importance, and immunotherapy is a new option that has the potential to transform the landscape of this disease. This treatment is developed to act on the changes within the immune system caused by cancer, including checkpoint inhibitors, which have recently shown great promise in the treatment of this disease and have recently been included in the adjuvant treatment of oesophageal cancer in many countries worldwide. This review will outline the mechanisms by which cancer evades the immune system in those diagnosed with oesophageal cancer and will summarize current and ongoing trials that focus on the use of our own immune system to combat disease.
Citation
To N, Evans RPT, Pearce H, Kamarajah SK, Moss P, Griffiths EA. Current and Future Immunotherapy-Based Treatments for Oesophageal Cancers. Cancers (Basel). 2022 Jun 24;14(13):3104. doi: 10.3390/cancers14133104
Type
Article